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Abstract 27 
Rationale: Previous studies suggest that group II metabotropic glutamate receptors (mGluR2/3) 28 
are involved in regulating ethanol seeking and consumption. Objective: The mGluR2/3 agonist 29 
LY379268 (LY37) and selective mGluR2 positive allosteric modulator biphenyl-indanone A 30 
(BINA) were used to investigate the relative contribution of mGlu2 and mGlu3 receptors on 31 
ethanol and sucrose seeking and consumption. A microinjection study was then performed to 32 
examine the role of nucleus accumbens (NAc) core mGluR2/3 on ethanol-seeking. Methods: 33 
For the systemic experiments, separate groups of male Wistar rats [LY37 (0-2.0 mg/kg); BINA 34 
(0-20 mg/kg)] were trained to complete a response requirement (RR) resulting in access to 10% 35 
ethanol or 2% sucrose (in separate groups) for a 20-minute drinking period. Animals then 36 
underwent consummatory testing (weekly drug injections with RR1) followed by appetitive 37 
testing (weekly drug injections followed by extinction session). A separate group of male Wistar 38 
rats was surgically implanted with bilateral guide cannulae directed towards the NAc core and 39 
had weekly microinjections followed by an extinction session. Results: Systemic administration 40 
of the mGluR2/3 agonist LY37 significantly reduced ethanol- and sucrose-seeking. The same 41 
treatment also reduced sucrose consumption and body weight (24-hours post injection). 42 
Systemic administration of the selective mGluR2 PAM BINA, however, had no effect on either 43 
seeking or consumption of ethanol or sucrose. Intra-accumbens core LY37 significantly reduced 44 
ethanol-seeking. Conclusions: These findings suggest that systemic mGluR2/3 agonism, but not 45 
allosteric modulation of mGluR2, reduces reinforcer seeking. In particular, NAc core group II 46 
mGluR may be involved in regulating ethanol-seeking.  47 
Keywords: Metabotropic Glutamate Receptors, LY379268, BINA, LY341495, Alcohol, Self-48 
Administration 49 
50 
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Introduction 51 
Group II metabotropic glutamate receptors (mGluRs), mGlu2 and mGlu3, are 52 
predominately presynaptically located Gαi/o associated G-protein coupled receptors highly 53 
expressed in the cortex, nucleus accumbens (NAc), striatum, amygdala, and hippocampus 54 
(Ohishi et al. 1998; Tamaru et al. 2001; Xi et al. 2002). Group II mGluRs negatively regulate 55 
synaptic glutamate release (Scanziani et al. 1997; Xi et al. 2002). Given their expression in 56 
brain regions associated with drug reinforcement and regulation of excitatory neurotransmission, 57 
group II mGluR agonists have been examined for possible involvement in regulating drug 58 
reinforcement. The non-selective group II mGluR agonist LY379268 (LY37) has been shown to 59 
reduce both operant self-administration and cue-induced reinstatement for several drugs of 60 
abuse including cocaine and ethanol (Baptista et al. 2004; Bossert et al. 2005; Bossert et al. 61 
2004; Kufahl et al. 2011; Liechti et al. 2007). Mixed findings have been reported for the effects 62 
of LY37 on alternative/natural reinforcers with either no effect (Baptista et al. 2004; Zhao et al. 63 
2006) or a reduction in alternative reinforcer seeking and/or consumption at the highest LY37 64 
dose tested (Jin et al. 2010; Kufahl et al. 2011; Liechti et al. 2007; Peters and Kalivas 2006). 65 
However, this high dose of LY37 has been shown to reduce locomotor behavior (Backstrom and 66 
Hyytia 2005; Kufahl et al. 2011) suggesting that the effect of LY37 on natural reinforcers may be 67 
due to sedative effects of LY37 at high doses. Further examination of the effects of systemic 68 
administration of LY37 on alternative reinforcer seeking and consumption is needed to clarify 69 
the specificity of mGluR2/3 in modulating ethanol reinforcement.  70 
Growing evidence suggests that the effects of non-selective Group II mGluR agonists, 71 
such as LY37, on decreasing drug self-administration and reinstatement of drug-seeking are not 72 
due to equal contributions of mGlu2 and mGlu3 receptor agonism. Mice lacking mGluR3 display 73 
normal cocaine self-administration, extinction, and reinstatement responding (Cannella et al. 74 
2013) while mGluR2 deficient mice display increased cocaine place preference (Morishima et al. 75 
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2005) and increased preference for and consumption of ethanol (Zhou et al. 2013). This 76 
suggests that loss of mGluR2, but not mGluR3, results in increased preference for and intake of 77 
drugs of abuse. Here the mGluR2 positive allosteric modulator Biphenyl indanone-A (BINA) was 78 
used to examine the role of mGluR2 in regulating ethanol-seeking and consumption. 79 
In the present study, the effect of moderate doses of systemic LY37 and BINA 80 
administration on ethanol-seeking and consumption were assessed using the sipper tube 81 
method (e.g., Czachowski et al. 2001). In this method, the seeking response (lever press) is 82 
procedurally separated from the consummatory response (drinking) allowing for discrete 83 
analysis of the effect of LY37 and BINA on each behavior independently. Given that prior 84 
systemic LY37 and BINA studies show either similar or reduced effects when comparing self-85 
administration to reinstatement responding (Backstrom and Hyytia 2005; Bossert et al. 2005; Jin 86 
et al. 2010; Liechti et al. 2007; Sidhpura et al. 2010), we hypothesized that systemic modulation 87 
of group II mGluRs, by either orthosteric agonism or mGlu2 positive allosteric modulation, would 88 
preferentially reduce ethanol seeking versus consumption in non-deprived Wistar rats using the 89 
sipper tube model. Furthermore, given the increasing evidence that the reduced ethanol-90 
seeking observed with systemic LY37 is due to agonism of mGlu2 but not mGlu3 receptors, we 91 
hypothesized that modulation of mGlu2 receptors via systemic administration of the selective 92 
mGluR2 PAM BINA would result in a similar efficacy in attenuating ethanol-seeking as observed 93 
with the mGluR2/3 agonist LY37.  94 
Ethanol has been shown to influence glutamatergic signaling following both acute and 95 
chronic administration, particularly within the NAc and ventral tegmental area (VTA). For 96 
instance, acute administration of low to moderate ethanol doses (0.5 – 1 g/kg) results in 97 
increased extracellular glutamate concentrations in the VTA, NAc, and hippocampus (Ding et al. 98 
2012; Moghaddam and Bolinao 1994; Selim and Bradberry 1996). Elevated NAc extracellular 99 
glutamate concentrations have also been observed during withdrawal following experimenter 100 
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administered ethanol (Melendez et al. 2005) and home cage ethanol drinking (Ding et al. 2013). 101 
Intra-accumbens administration of LY37 in “post-dependent” C57BL/6J mice reduced 2-hour 102 
limited access home cage ethanol drinking (Griffin et al. 2014). Since inactivation of the NAc 103 
core but not NAc shell has been shown to reduce responding to an ethanol-conditioned stimulus 104 
in a novel context (Chaudhri et al. 2010), the NAc core subregion was selected for our initial 105 
microinjection experiment to begin clarifying the loci of action of mGluR2/3 agonists in regulating 106 
ethanol-seeking. As intra-accumbens LY37 administration produced nonspecific reductions in 107 
locomotor activity in alcohol-preferring P rats (Besheer et al. 2010), in the present experiment 108 
the non-sedative group II antagonist LY341495 (LY34) (Chi et al. 2006) was microinjected into 109 
NAc core following systemic agonist LY37 administration. We hypothesized that NAc core 110 
administration of mGluR2/3 antagonist LY34 would attenuate the suppressive effects of 111 
systemic LY37 administration on ethanol-seeking suggesting the involvement of NAc core 112 
mGluR2/3 in the regulation of ethanol-seeking.  113 
Material and methods 114 
Animals 115 
Male Wistar rats (Hsd:WI, Harlan Labs, Indianapolis, IN), weighing 165 - 210 g at the 116 
beginning of the experiment, were single housed on a 12-hour light/dark cycle (lights on at 117 
0500). Animals had ad libitum access to both food and water except for a mild water restriction 118 
during the first week of training. Animal care and procedures were in accordance with NIH 119 
Guidelines for the Care and Use of Laboratory Animals (2011) and approved by the IUPUI 120 
Institutional Animal Care and Use Committee (IACUC). 121 
Apparatus 122 
Sessions were conducted daily (5 days/week) in operant chambers (30x30x24.5 cm; 123 
Med-Associates, St Albans, VT). Chambers were located in sound attenuated enclosures with 124 
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exhaust fans to mask external noise. The chambers were equipped with a house light, a single 125 
retractable lever, and a single retractable graduated sipper tube located on the wall opposite the 126 
lever. The sipper tube consisted of a graduated cylinder tube with a rubber stopper and 127 
stainless steel tube with two ball bearings to prevent leakage. Med-Associates software was 128 
used to control input and output from each chamber.  129 
Systemic Experiment: Training 130 
Upon arrival, animals were weighed and handled twice during the week preceding initial 131 
training (see Figure 1a for an overview of the entire experiment). Sessions were conducted at 132 
the same time daily during the lights on portion of the light/dark cycle. During initial training, 133 
animals underwent a brief (14-18 hr) water deprivation prior to the first training session, followed 134 
by a mild 2-4 day water restriction to facilitate acquisition of lever-press responding. Food and 135 
water were available ad libitum for the remainder of the testing. 136 
Separate groups of rats (LY37 and BINA) were initially trained to lever press on a FR1 137 
schedule for 15 seconds of access to a 10% oral sucrose reinforcer. Once lever press was 138 
acquired (1-3 sessions), the schedule was increased gradually over sessions to a final FR4 139 
schedule while the sucrose was gradually reduced using a modified sucrose-fade procedure 140 
(Samson 1986). For the sucrose-fade, over a 3-week period, the sucrose concentration was 141 
gradually reduced over sessions while ethanol was gradually faded into the solution (for ethanol 142 
groups). Final reinforcer concentrations were 2% sucrose (sucrose groups) and 10% ethanol 143 
(ethanol groups). The FR4 schedule was then discontinued and a response requirement (RR) 144 
was implemented allowing for procedural separation of seeking from consumption. For this, 145 
animals had 20 minutes to complete the RR (initially 4 lever presses). Once the RR was met, 146 
the lever was retracted and the sipper tube was inserted into the chamber. Animals then had 20 147 
minutes of unrestricted access to the reinforcer. The RR was gradually increased over sessions 148 
to a final RR of 10 lever presses. 149 
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Systemic Experiment: Drinking Test Phase 150 
Following training, animals underwent a six-week Drinking Test Phase. Animals had 151 
once weekly test sessions on Thursday with a RR of 1 lever-press so that minimal effort was 152 
required to gain access to the reinforcer. The other four sessions were non-injection sessions 153 
with a RR of 10. Animals were first habituated to the test procedure with a systemic vehicle 154 
injection then received IP drug injections (0.0, 0.3, 1.0, 1.5, and 2.0 mg/kg LY37; 0, 5, 10, and 155 
20 mg/kg BINA) in a balanced design (random dose order across injection sessions with doses 156 
balanced across animals: 3 animals/dose and 3 doses/injection session). LY37 and BINA doses 157 
used were selected based on the literature for drug doses not shown to influence locomotor 158 
behavior (Backstrom and Hyytia 2005; Jin et al. 2010; Kufahl et al. 2011). Following the drinking 159 
test phase, animals had a three-week period during which no drugs were administered and the 160 
RR was gradually increased from 10 to 20 lever presses. 161 
Systemic Experiment: Seeking Test Phase 162 
Animals then underwent a six-week Seeking Test Phase using the same vehicle 163 
habituation, followed by weekly drug injections with doses administered in a balanced design. 164 
During the weekly test session, systemic drug injection was followed by a non-reinforced 165 
extinction session. During the extinction session, animals had 20 minutes of access to the lever, 166 
but did not gain access to the reinforcer. To control for possible scent cues, filled bottles were 167 
placed on the retracted holders. Animals had weekly reinforced vehicle injection sessions (on 168 
Tuesdays) to reduce the likelihood of systemic injection predicting an extinction session. The 169 
other three sessions were normal reinforced sessions.  170 
Microinjection experiment (Figure 1b) 171 
The apparatus and training were identical to those of the systemic experiment. Following 172 
surgery (see below), animals were allowed to reacquire lever press responding with the RR 173 
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gradually increased over sessions to a final response requirement of 15. NAc core blockade of 174 
systemic mGluR2/3 agonist induced suppression of ethanol-seeking was performed using the 175 
non-selective group II mGluR antagonist LY34. For microinjections, rats were gently restrained 176 
in a small holding tub (27 x 17 x 12 cm). Each obturator was removed and replaced with a 177 
stainless-steel injector (33 gauge) that extended 1 mm beyond the end of the guide cannulae. 178 
Drug solutions were delivered bilaterally in a volume of 0.5 µL/side over a one-minute period 179 
using 25.0 µL Hamilton syringes and KD Scientific Infusion Pumps (Model 101; KD Scientific 180 
Inc., Holliston, MA). The drug was then allowed 30 seconds to diffuse prior to removal of the 181 
injector. Following injection, obturators were replaced and the animal was returned to the animal 182 
carrier prior to the operant session. Animals had weekly microinjection extinction test sessions 183 
on Thursdays (identical to extinction sessions during seeking test phase of systemic experiment) 184 
with “normal” reinforcer sessions the remaining four days. To prevent an association of the 185 
microinjection procedure with the extinction session, a reinforced sham session and a no 186 
injection extinction session occurred the week following the first and third sets of microinjections, 187 
respectively. Animals were initially habituated to the microinjection procedure with a systemic 188 
vehicle injection plus sham microinjection (<10 mm injectors placed into guide cannulae with no 189 
fluid administered) followed by an extinction session. Animals then received each of four sets of 190 
systemic injection plus NAc core microinjection in a balanced design (systemic vehicle + NAc 191 
core vehicle, systemic LY37 + NAc core vehicle, systemic LY37 + NAc core LY34, and systemic 192 
vehicle + NAc core LY34). After the final set of systemic injection plus NAc core microinjections, 193 
animals received a microinjection of LY37 (0.5 µg/0.5 µL/side) without systemic injection to 194 
determine the effects of agonist administration into the NAc core. 195 
Surgery 196 
Following training, animals were surgically implanted with bilateral guide cannulae 197 
directed towards the NAc core. Thirty minutes prior to surgery, the non-steroidal anti-198 
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inflammatory drug (NSAID) carprofen was administered (5 mg/kg; sc) for pain relief. Rats were 199 
anesthetized with sodium pentobarbital (60 mg/kg, ip), the top of the head shaved, and the rat 200 
placed in the stereotaxic apparatus (Benchmark Digital Stereotaxic; myNeurolab, St. Louis, MO) 201 
with incisor bar set at 3.3 mm below the interaural line. Stainless steel guide cannulae (13 mm; 202 
26 gauge) were implanted bilaterally terminating 1 mm dorsal to the NAc core using bregma, 203 
midline, and dura surface as reference (AP +1.6, ML ± 1.6, DV - 6.0; Paxinos and Watson 204 
1998) . Removable wire obturators (13mm length; 33 gauge) were placed into the guide 205 
cannulae to limit obstruction and maintain patency. Following surgery, animals had two days to 206 
recover prior to resuming operant sessions. Animals were checked daily to ensure proper 207 
wound healing and lack of infection. 208 
Histology 209 
Following the completion of the final operant session, the animals were deeply 210 
anesthetized with sodium pentobarbital (120 mg/kg, ip) and transcardially perfused with 211 
phosphate buffered saline (PBS) then 10% formalin. The brains were removed and stored in 10% 212 
formalin. The brains were sliced (60 µm sections) using a cryostat (Leica CM1950, Leica 213 
Microsystems Inc., Buffalo Grove, IL), mounted, and stained using cresyl violet. Site verification 214 
was performed using a light microscope. Only animals with confirmed bilateral cannulae 215 
placement in the NAc core were included in the analyses. 216 
Drugs 217 
Ethanol solutions were prepared volume/volume in water using 95% ethanol. Sucrose 218 
and sucrose/ethanol solutions were prepared weight/volume. The non-selective group II mGluR 219 
agonist LY379268 [(1R,4R,5S,6R)-4-Amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid] 220 
(Santa Cruz Biotechnology, Inc., Dallas, TX) was dissolved in sterile 0.9% saline and injected at 221 
a volume of 1.0 mL/kg body weight. The selective mGluR2 positive allosteric modulator BINA 222 
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[Biphenyl-indanone A (3’-[[(2-Cyclopentyl-2,3-dihydro-6,7-dimethyl-1-oxo-1H-inden-5-223 
yl)oxy]methyl]-[1,1’-biphenyl]-4-carboxylic acid)] (Santa Cruz Biotechnology, Inc., Dallas, TX; 224 
Tocris Bioscience, Minneapolis, MN) was dissolved in 0.5% dimethyl sulphoxide (DMSO) and 1% 225 
sodium hydroxide (NaOH) diluted with sterile water then titrated to a final pH of 7.4 using 1% 226 
lactic acid and injected at a volume of 5 mL/kg body weight. Sterile saline and sterile water plus 227 
0.5% DMSO and 1% NaOH titrated to a final pH of 7.4 using 1% lactic acid were vehicle 228 
treatments for LY37 and BINA respectively. For systemic experiments, LY37 (0-2.0 mg/kg) and 229 
BINA (0-20 mg/kg) were administered 30 and 60 minutes prior to the operant session 230 
respectively.  231 
For microinjections, LY37 was dissolved in artificial cerebrospinal fluid (aCSF; Harvard 232 
Apparatus, Holliston, MA) and the non-selective group II mGluR antagonist LY341495 [(2S)-2-233 
Amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid] (Santa Cruz 234 
Biotechnology, Inc., Dallas, TX) was dissolved in 20% DMSO plus aCSF. Sterile aCSF plus 20% 235 
DMSO was used as the vehicle treatment for LY34. LY37 (1.5 mg/kg) was administered ip 30 236 
minutes prior to the microinjection and LY34 (1.0 µg/side) was administered 10 minutes prior to 237 
the start of the operant session. For the final microinjection, LY37 (0.5 µg/side) was 238 
administered 10 minutes prior to the start of the operant session. 239 
Data Analyses 240 
Daily session intakes of ethanol and sucrose were determined from the change in 241 
volume in the sipper tube (mL). Ethanol intake (g/kg) and sucrose intake (mL/kg) were 242 
calculated from session intake and daily body weight measures. Total lever presses, latency to 243 
first lever press (in sec), and latency to first lick (in sec) were recorded for each session. Ethanol 244 
and sucrose consumption data were analyzed separately using one-way within-subject repeated 245 
measures analysis of variance (RM ANOVA). To examine potential protracted effects of the 246 
acute drug administration on reinforcer intake, change in intake was computed by subtracting 247 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 11
the intake during the reinforced session 24-hrs following the drug treatment from the intake 248 
during the reinforced session 24-hrs prior to drug treatment (i.e., Friday intake minus 249 
Wednesday intake). For systemic administration experiments, appetitive responding, lick 250 
latencies, and body weight change [body weight 24-hrs post-injection (Friday) minus body 251 
weight 1-hr prior to injection (Thursday)] were analyzed using two-way RM ANOVAs with dose 252 
and reinforcer as factors. For NAc microinjection experiment appetitive responding, lever press 253 
latency, and body weight change were analyzed using one-way within-subject RM ANOVA. The 254 
final LY37 microinjection session was not included in the original balanced design; therefore, the 255 
systemic vehicle plus NAc core vehicle and NAc core LY37 were compared using a paired 256 
samples t-test. Post-hoc comparisons were performed using Student-Newman-Keuls test 257 
(p<0.05). All analyses were conducted using SigmaStat3.5 (Systat Software, Inc., Chicago, IL). 258 
Results 259 
Systemic Experiment 260 
One animal in the LY37 ethanol group had poor behavioral performance during both 261 
testing phases and was removed from analysis (LY37 ethanol n=8; LY37 sucrose n=9; BINA 262 
ethanol n=9; BINA sucrose n=9). Prior to drug injections, ethanol-reinforced animals consumed 263 
a mean of 0.64 ± 0.06 g/kg of ethanol for LY37 and 0.67 ± 0.04 g/kg for BINA. Sucrose-264 
reinforced animals consumed a mean of 3.69 ± 0.32 mL/kg of sucrose for LY37 and 4.12 ± 0.28 265 
mL/kg for BINA (data not shown).  266 
Drinking Test Phase 267 
For the Drinking Test Phase, a significant effect of LY37 treatment on sucrose intake 268 
(mL/kg) was observed [F(4, 32) = 12.887, p<0.001] with post hoc analyses indicating a 269 
significant decrease in sucrose consumption at the 1.5 and 2.0 mg/kg dose (p<0.01) compared 270 
to LY37 vehicle (figure 2a). No effect of LY37 on ethanol consumption (g/kg) was observed [F(4, 271 
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28) = 1.65, p=0.19] (figure 2b). No effect of BINA on either sucrose [F(3, 24) =0.418, p=0.74] or 272 
ethanol consumption was observed [F(3, 24) =1.34, p=0.28] (figure 2c and 2d). No protracted 273 
effect of either LY37 or BINA was observed for either ethanol [LY37: F(4,28) = 1.975, p=0.13; 274 
BINA: F(3,24) = 1.154; p=0.35] or sucrose consumption [LY37: F(4,32) = 2.309, p=0.08; BINA: 275 
F(3,24) = 0.254; p=0.86] as measured by the difference in intake during reinforced session 24-276 
hrs following drug treatment (Friday session) from intake during reinforced session 24-hrs prior 277 
to drug treatment (Wednesday session; data not shown).  278 
Seeking Test Phase 279 
A significant main effect of LY37 on appetitive responding was observed [F(4, 60) 280 
=30.33, p<0.001]. Post hoc analyses indicate that LY37 significantly (p<0.001) decreased 281 
seeking at the 1.0, 1.5, and 2.0 mg/kg LY37 doses (figure 3a). No interaction of treatment x 282 
reinforcer was observed [F(4, 60) =1.682, p=0.17]. A main effect of BINA treatment [F(3, 48) 283 
=3.1587, p<0.05] on seeking was observed (figure 3b). Post hoc analyses indicate that the 284 
effect was due to a significant difference between the 5 mg/kg and 20 mg/kg dose (p=0.03) and 285 
a moderate decrease in seeking at the 20 mg/kg dose compared to vehicle (p = 0.055). No 286 
protracted effect of either LY37 or BINA was observed for either ethanol [LY37: F(4,26) = 1.167, 287 
p=0.35; BINA: F(3,23) = 1.072; p=0.38] or sucrose consumption [LY37: F(4,32) = 0.879, p=0.49; 288 
BINA: F(3,24) = 0.693; p=0.57] as measured by the difference in intake during reinforced 289 
session 24-hrs following drug treatment (Friday session) from intake during reinforced session 290 
24-hrs prior to drug treatment (Wednesday session; data not shown).  291 
Latency to First Lick 292 
The latency to first lick is the time (in sec) following successful completion of the lever 293 
press response requirement (RR1) for the animal to turn, traverse the chamber, and make initial 294 
contact with the sipper tube. Average lick latency for vehicle administration was 2.35 ± 0.59 295 
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seconds in the LY37 groups and 1.61 ± 0.13 seconds in the BINA groups. A significant main 296 
effect of LY37 on latency to first lick was observed [F(4, 54) =3.39, p<0.05] (table I). However, 297 
post hoc analysis revealed that this effect was due to a within dose difference in first lick latency 298 
(1.5 mg/kg compared to 0.3 and 1.0 mg/kg doses, with the high dose of 2.0 mg/kg not 299 
significantly different from any other dose or vehicle). No effect of BINA administration was 300 
observed for latency to first lick [F(3, 48) =1.63, p=0.20] (table I). Overall, no dose of either the 301 
mGluR2/3 agonist LY37 or mGluR2 PAM BINA significantly increased the latency to first lick 302 
compared to the vehicle. 303 
Body Weight 304 
The change in body weight between injection session and subsequent session (24 hrs 305 
post-injection) during the drinking and seeking test phases was computed to examine possible 306 
nonspecific effects of systemic LY37 and BINA administration. A significant main effect of LY37 307 
on body weight during the drinking test phase was observed [F(4, 64) =17.99, p<0.001]. Post 308 
hoc analyses indicate that LY37 significantly (p<0.01) decreased body weight 24 hours following 309 
systemic injection at the 1.0, 1.5, and 2.0 mg/kg LY37 doses relative to vehicle (table II). No 310 
interaction of treatment x reinforcer was observed [F(4, 64) =1.35, p=0.26]. Similarly, a 311 
significant main effect of LY37 on body weight during the seeking test phase was observed [F(4, 312 
64) =10.271, p<0.001]. Post hoc analyses indicate a significant (p<0.01) reduction in body 313 
weight 24 hours following systemic LY37 administration at the 1.0, 1.5, and 2.0 mg/kg doses 314 
relative to vehicle (table II). No interaction of treatment x reinforcer was observed [F(4, 64) 315 
=0.12, p=0.98].  No effect of systemic BINA administration was observed for body weight during 316 
either the drinking test phase [F(3, 48) =0.56, p=0.65] or seeking test phase [F(3, 48) =1.337, 317 
p=0.27] (table II). Overall, systemic administration of the non-specific mGluR2/3 agonist LY37, 318 
but not the mGluR2 PAM BINA, consistently decreased body weight 24-hours following 319 
systemic administration. 320 
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Microinjection Experiment 321 
Four subjects were removed from the experiment prior to the start of the microinjection 322 
testing due to poor behavioral performance. Of the remaining subjects, six subjects were 323 
confirmed to have bilateral cannulae placement with injection into the NAc core (n=6). During 324 
the week prior to the sham habituation injection, animals consumed a mean of 0.44 ± 0.05 g/kg 325 
ethanol. 326 
Appetitive Responding 327 
For systemic plus NAc core mGluR2/3 modulation, a significant main effect of treatment 328 
on appetitive responding was observed [F(4, 20) =12.58, p<0.001]. Post hoc analyses indicate 329 
that systemic LY37 plus NAc core vehicle decreased seeking compared to systemic vehicle plus 330 
NAc core vehicle (p<0.01) (figure 4). Systemic LY37 plus NAc core LY34 was also shown to 331 
decrease seeking compared to systemic vehicle plus NAc core vehicle (p<0.05). However, 332 
appetitive responding following systemic LY37 plus NAc core LY34 was not significantly 333 
different from responding during systemic LY37 plus NAc core vehicle (p=0.56). Administration 334 
of mGluR2/3 antagonist LY34 following systemic vehicle administration did not decrease 335 
seeking compared to systemic vehicle plus NAc core vehicle (p=0.85). Given the inability of NAc 336 
core antagonist to attenuate the systemic agonist induced suppression of ethanol-seeking, 337 
agonist (LY37) was microinjected into the NAc core to clarify whether NAc core group II mGluRs 338 
are involved in the regulation of ethanol-seeking. As this injection was not counterbalanced 339 
across animals, the data were analyzed using a paired samples t-test (NAc core LY37 vs 340 
systemic vehicle plus NAc core vehicle). Appetitive responding following NAc core LY37 341 
administration was significantly decreased compared to systemic vehicle plus NAc core vehicle 342 
[t(5)=2.58, p<0.05].  343 
Latency to First Lever Press 344 
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Examination of lever press latency can be confounded for sessions in which the animal 345 
does not emit a lever press response (since this may indicate either sedation or a decrease in 346 
reinforcer seeking). Therefore, analysis of lever press latency was performed using both a 347 
conservative approach (non-response interpreted as seeking behavior and trials excluded from 348 
analysis) and liberal approach [non-response interpreted as diminished locomotion and 349 
maximum latency (1200 sec) used]. Neither the conservative [F(3,11)=0.355, p=0.79] nor liberal 350 
[F(3,15)=0.314, p=0.82] analyses indicated any effects of treatment on lever press latency (table 351 
I). The effect of NAc core LY37 administration was analyzed separately using a pair-samples t-352 
test (NAc core LY37 vs systemic vehicle plus NAc core vehicle). Neither the conservative [t(2) 353 
=0.81, p=0.51] nor liberal [t(5) =-1.74, p=0.14] analyses yielded significant effects of treatment 354 
suggesting that NAc core administration of neither LY34 nor LY37 had a significant effect on 355 
latency to initiate responding. 356 
Body Weight 357 
A significant main effect of systemic treatment on the change in body weight between 358 
injection session and subsequent session was observed [F(1, 10) =8.87, p<0.01]. Post hoc 359 
analyses indicate that systemic LY37 administration significantly (p<0.01) decreased body 360 
weight 24 hours following injection (table II). The average change in body weight following 361 
systemic LY37 administration was -21.4 ± 2.1 g.  362 
Discussion 363 
Overall, systemic administration of the group II mGluR agonist LY37 significantly 364 
decreased reinforcer seeking and selectively decreased sucrose, but not ethanol, consumption 365 
at doses not shown to affect the latency to initiate responding. As well, in two separate 366 
experiments, systemic LY37 administration was noted to decrease body weight 24-hours 367 
following administration. Aside from the body weight change, animals were healthy and not 368 
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observed to be in distress. Systemic administration of the mGluR2 PAM BINA had no effect on 369 
reinforcer consumption and no dose-related or reinforcer-specific pattern of effects on 370 
reinforcer-seeking. Systemic administration of BINA also had no effect on body weight. Finally, 371 
no protracted effect of acute administration of LY37 or BINA on either sucrose or ethanol 372 
consumption was observed. 373 
Prior studies examining the effect of systemic group II mGluR agonists and PAM 374 
administration on operant self-administration used fixed ratio reinforcement schedules that 375 
require animals to engage in a seeking response prior to consumption of a small amount of the 376 
reinforcer across the duration of the session (Backstrom and Hyytia 2005; Jin et al. 2010; Liechti 377 
et al. 2007; Sidhpura et al. 2010). Such studies, therefore, measure a mixture of seeking and 378 
consumption. In the present study, a “sipper tube” method (e.g., Czachowski et al. 2001) was 379 
used to assess the effect of moderate doses of systemic LY37 and BINA administration on 380 
ethanol-seeking and consumption. In this method, a once-daily seeking response (lever press) 381 
is procedurally separated from the consummatory response (drinking) allowing for discrete 382 
analysis of the effect of LY37 and BINA on each behavior independently. Previous studies have 383 
reported a decrease in operant ethanol self-administration using a fixed ratio schedule following 384 
systemic LY37 administration (Backstrom and Hyytia 2005; Sidhpura et al. 2010). This is in 385 
agreement with our finding of reduced ethanol-seeking following systemic administration of the 386 
mGluR2/3 agonist LY37. However, here we observed that systemic LY37 administration does 387 
not significantly affect ethanol consumption. The lack of LY37 effect on ethanol consumption 388 
suggests a limitation of a fixed ratio procedure in that it assesses a combination of reinforcer 389 
seeking and consumption across the session while the sipper tube model allows for examination 390 
of reinforcer consumption specifically without the seeking confound. Together these findings 391 
suggest that regulation of neurotransmission via mGluR2/3 activation specifically influences 392 
ethanol-seeking with no effect on ethanol consumption. 393 
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More importantly, systemic administration of the group II mGluR agonist LY37 was 394 
observed to reduce seeking and consumption of an alternative reinforcer (sucrose) at doses not 395 
found to significantly affect start latencies. Of the previous studies that have examined the effect 396 
of LY37 on seeking and/or consumption of an alternative reinforcer, either no effect (Baptista et 397 
al. 2004; Zhao et al. 2006) or only at the highest dose of LY37 tested (3 mg/kg), was alternative 398 
reinforcer seeking and/or consumption reduced (Kufahl et al. 2011; Liechti et al. 2007; Peters 399 
and Kalivas 2006). However, this same dose of LY37 (3 mg/kg) shown to reduce seeking and 400 
consumption of food reinforcers was also shown to significantly reduce spontaneous locomotor 401 
behavior (Kufahl et al. 2011) suggesting that the observed effect of LY37 on reinforcer seeking 402 
and consumption is due to the sedative effects of LY37. However, here we demonstrated that 403 
LY37 does, in fact, reduce not only sucrose seeking but also sucrose consumption and body 404 
weight 24-hours following systemic administration at doses not observed to result in significant 405 
changes in response initiation. Further, a significant reduction in both sucrose seeking and body 406 
weight was observed following administration of 1.0 mg/kg LY37, a dose which has previously 407 
been shown to have no significant effect on spontaneous locomotor behavior (Kufahl et al. 408 
2011). These findings indicate that the behavioral effects of group II mGluRs agonists are not 409 
specific to ethanol-seeking, but rather agonism of mGluR2/3 results in a general reduction in the 410 
incentive salience of reinforcers. This may be due to a possible transient drug-induced 411 
anhedonic-like state or malaise. Conversely, as sucrose but not ethanol consumption was 412 
reduced following LY37 administration, the effect of systemic LY37 on seeking and consumption 413 
may be due to the involvement of group 2 mGluRs in regulating feeding and satiety. Further 414 
research is needed to clarify the mechanism by which systemic mGluR2/3 agonism reduces 415 
seeking and consumption of natural reinforcers. 416 
Systemic administration of the selective mGluR2 PAM BINA (0-20 mg/kg, ip) did not 417 
significantly affect seeking or consumption of either ethanol or sucrose. Previously, BINA was 418 
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shown to decrease both cocaine self-administration (20 and 40 mg/kg) and cue-induced 419 
reinstatement of cocaine seeking (10, 20, and 40 mg/kg) with no effect on food self-420 
administration or cue-induced reinstatement of food-seeking (Jin et al. 2010). It is possible that 421 
the lack of BINA effect on ethanol seeking and/or consumption observed here was due to the 422 
Wistar rats used not expressing functional mGlu2 receptors given the recent findings of a 423 
premature stop codon mutation in mGluR2 (Grm2 cys407*) for some commercially available 424 
Wistar rat populations (Wood et al. 2017). However, this is unlikely as Wood et al (2017) did not 425 
observe the mutation in this strain of Harlan Wistar rats (Hsd:WI, n=48). It is also possible that a 426 
higher dose of BINA may have decreased reinforced responding and/or intake, but note that the 427 
high dose was twice the dose necessary to decrease cocaine seeking. 428 
Interpretation of the separate contribution of mGlu2 and mGlu3 receptors in reinforcer 429 
seeking is difficult with systemic LY37 and BINA administration due to the differing mechanisms 430 
of action of the drugs (i.e., orthosteric agonism compared to positive allosteric modulation, 431 
respectively). The lack of a significant effect of systemic BINA administration on ethanol seeking 432 
could suggest that the decreased reinforcer seeking observed following systemic LY37 433 
administration is driven primarily by agonist action at mGlu3 receptors. However, previous 434 
studies have shown that rats homozygous for a mGluR2 stop codon (Grm2 cys407*) which 435 
results in loss of functional mGluR2 expression (Corda et al. 2014; Manzo et al. 2012; Zhou et 436 
al. 2013) and mGluR2 knockout mice (Zhou et al. 2013) have increased preference for and 437 
consumption of ethanol. This suggests that loss of mGluR2 contributes to increased ethanol 438 
seeking and/or consumption. Due to mechanistic differences between BINA and LY37, the 439 
different contributions of mGluR2 and mGluR3 agonism on ethanol reinforcement is difficult to 440 
determine unequivocally from our findings. Subsequent work with yet unavailable subtype-441 
specific orthosteric agonists may be able to disentangle the relative contributions of mGlu2 and 442 
mGlu3 receptors in ethanol reinforcement. 443 
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Appetitive responding following systemic LY37 plus NAc core LY34 was not significantly 444 
different from responding following systemic LY37 alone. This inability of NAc core mGluR2/3 445 
blockade to alter the LY37-induced reduction in appetitive responding suggests that NAc core 446 
mGluR2/3 may not be involved in the regulation of ethanol-seeking. However, intra-accumbens 447 
core microinjection of LY37 did significantly reduce ethanol-seeking without affecting the latency 448 
to first lever press. The lack of attenuation of LY37 suppression of ethanol-seeking by NAc core 449 
LY34 may, therefore, be due to methodological factors such as the dose of LY34 chosen or the 450 
use of systemic administration of an agonist preceding the brain-site specific administration of 451 
an antagonist. 452 
Using a behavioral model that allows for discrete separation of reinforcer seeking and 453 
consumption, we found that systemic administration of the mGluR2/3 agonist LY37, but not 454 
mGluR2 PAM BINA, decreased ethanol-seeking but not consumption contrary to previous 455 
studies that did not separate seeking from consumption. This novel finding implies that group II 456 
mGluR agonists could be an efficacious treatment approach for craving-related behaviors that 457 
generate reinforcer seeking. As well, it suggests a lack of efficacy of group II mGluR agonists for 458 
targeting drinking behavior specifically (e.g., treatment of binge drinking). Intra-accumbens core 459 
administration of LY37 was also shown to significantly reduce ethanol-seeking, further 460 
implicating group II mGluRs in ethanol-reinforced appetitive behavior. Notably, administration of 461 
LY37 also decreased sucrose consumption and body weight 24-hours following systemic 462 
administration suggesting that group II mGluRs are not specific to regulation of drug seeking but 463 
may be broadly involved in regulating incentive salience of reinforcers.  464 
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Table Captions. 565 
 566 
Table I Mean (±SEM) latency (in seconds) to lick or lever press response for systemic and 567 
microinjection experiments. For systemic experiments the latency to first lick is the 568 
duration of time (in seconds) for the animal to traverse the chamber and make initial 569 
contact with the sipper tube following completion of the RR1 lever response. No effect of 570 
systemic administration of LY379268 or BINA compared to vehicle baseline latency was 571 
observed for latency to first lick. For microinjection experiment the latency to first lever 572 
press following systemic injection [with non-response sessions excluded from analysis 573 
(conservative latency) and non-response as maximal latency (liberal latency)] of the non-574 
selective group II mGluR agonist LY379268 (1.5 mg/kg) or vehicle followed by intra-575 
accumbens core administration of non-selective group II mGluR antagonist LY341495 576 
(1.0 µg/side) or vehicle. Additional microinjection of LY379268 (0.5 µg/side) without 577 
systemic injection was also performed. No significant effect of NAc core LY34 or LY37 578 
administration was observed for latency to first lever press. 579 
 580 
Table II Change in body weight (g) between injection session on Thursday and subsequent 581 
session (roughly 24 hours post-injection) on Friday. For systemic experiments, a 582 
significant reduction in body weight was observed at the 1.0, 1.5, and 2.0 mg/kg doses 583 
of LY379268 for both drinking and seeking test phases. No significant effect of systemic 584 
administration of BINA on body weight was observed for any dose tested during both 585 
drinking and seeking test phases. For the microinjection experiment a significant 586 
reduction in body weight was observed for systemic LY379268 administration. (* p<0.05) 587 
  588 
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Figure Captions. 589 
 590 
Fig. 1  Overview systemic experiments training and testing phases (a) and microinjection 591 
timeline (b). 592 
 593 
Fig. 2  Effect of LY379268 (a, b) and BINA (c, d) on Sucrose and Ethanol Consumption. 594 
Sucrose and ethanol consumption following weekly systemic drug injections (n=8-595 
9/group). A significant reduction in sucrose consumption was observed at the 1.5 and 596 
2.0 mg/kg doses of LY37 relative to vehicle. No effect of systemic administration LY37 597 
on ethanol consumption was observed for any dose tested. No effect of systemic 598 
administration BINA on ethanol or sucrose consumption was observed for any dose 599 
tested. (* p<0.05) 600 
 601 
Fig. 3  Effect of LY379268 (a) and BINA (b) on Sucrose and Ethanol Seeking. Appetitive 602 
responding for sucrose and ethanol following weekly systemic drug injection (n=8-603 
9/group). A significant reduction in seeking was observed at the 1.0, 1.5, and 2.0 mg/kg 604 
doses of LY37 relative to vehicle. No difference from vehicle responding was observed 605 
for appetitive responding for any dose of BINA tested. (* p<0.05) (*** p<0.001) 606 
 607 
Fig. 4  Effect of Intraaccumbens Core Antagonist on Systemic Agonist Induced Suppression of 608 
Ethanol -Seeking. Schematic diagrams adapted from the rat brain atlas (Paxinos and 609 
Watson, 1998) representing bilateral cannula placement (filled circles = microinjection 610 
site) in nucleus accumbens (fig 4a; n = 6). Each section represents approximate position 611 
in anteroposterior plane relative to bregma, and all placements were in the nucleus 612 
accumbens core. Subjects with cannula placement outside of nucleus accumbens core 613 
were not included in the data analyses and are not shown here. Appetitive responding 614 
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for ethanol following systemic injection of the non-selective group II mGluR agonist 615 
LY379268 (1.5 mg/kg) or vehicle followed by intra-accumbens core administration of 616 
non-selective group II mGluR antagonist LY341495 (1.0 µg/side) or vehicle (figure 4b; 617 
n=6/group). Additional microinjection of LY379268 (0.5 µg/side) without systemic 618 
injection was also performed. A significant reduction in ethanol-seeking was observed 619 
with systemic LY37 plus NAc core vehicle, systemic LY37 plus NAc core LY34 620 
compared to systemic vehicle plus NAc core vehicle. Ethanol-seeking was also reduced 621 
following NAc core administration of LY37 compared to systemic vehicle plus NAc core 622 
vehicle. (* p<0.05) 623 
 624 
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Highlights: 
• Systemic administration of LY379268 (LY37) and biphenyl indanone-A (BINA). 
• LY37 reduced ethanol seeking without influencing ethanol consumption. 
• Intraaccumbens core LY37 significantly reduced ethanol seeking. 
• BINA had no effect on seeking or consumption of either ethanol or sucrose. 
• LY37 significantly reduced sucrose seeking, sucrose consumption, and body weight. 
